JP2020529838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529838A5 JP2020529838A5 JP2019572402A JP2019572402A JP2020529838A5 JP 2020529838 A5 JP2020529838 A5 JP 2020529838A5 JP 2019572402 A JP2019572402 A JP 2019572402A JP 2019572402 A JP2019572402 A JP 2019572402A JP 2020529838 A5 JP2020529838 A5 JP 2020529838A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 148
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 102000016978 Orphan receptors Human genes 0.000 claims description 4
- 108070000031 Orphan receptors Proteins 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 4
- 201000000053 blastoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000008184 embryoma Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1710836.6A GB201710836D0 (en) | 2017-07-05 | 2017-07-05 | ROR1 Car T-Cells |
| GB1710836.6 | 2017-07-05 | ||
| PCT/GB2018/051915 WO2019008378A1 (en) | 2017-07-05 | 2018-07-05 | Ror1 car t-cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529838A JP2020529838A (ja) | 2020-10-15 |
| JP2020529838A5 true JP2020529838A5 (https=) | 2021-08-12 |
| JP7179030B2 JP7179030B2 (ja) | 2022-11-28 |
Family
ID=59592474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572402A Active JP7179030B2 (ja) | 2017-07-05 | 2018-07-05 | Ｒｏｒ１ ｃａｒ ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11723925B2 (https=) |
| EP (1) | EP3649150B1 (https=) |
| JP (1) | JP7179030B2 (https=) |
| CN (1) | CN110997709B (https=) |
| AU (1) | AU2018295478A1 (https=) |
| CA (1) | CA3068197A1 (https=) |
| GB (1) | GB201710836D0 (https=) |
| MX (1) | MX2019015352A (https=) |
| WO (1) | WO2019008378A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| CN114929751B (zh) * | 2019-09-27 | 2024-11-05 | 南京艾美斐生物医药科技有限公司 | Ror1特异性嵌合抗原受体及其治疗应用 |
| KR20230053602A (ko) * | 2020-08-24 | 2023-04-21 | 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 | 항-ror1 항체 및 관련된 이중특이적 결합 단백질 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CN114133457B (zh) * | 2021-12-08 | 2022-08-19 | 郑州源创吉因实业有限公司 | 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用 |
| WO2023186100A1 (zh) * | 2022-04-02 | 2023-10-05 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN118440200B (zh) * | 2023-04-21 | 2025-05-16 | 星奕昂(上海)生物科技有限公司 | 靶向ror1的抗体及其应用 |
| WO2025006880A1 (en) * | 2023-06-29 | 2025-01-02 | Caribou Biosciences, Inc. | Diagnostic and therapeutic methods for use with ror1 antagonists |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0920798A (ja) * | 1995-07-11 | 1997-01-21 | Asahi Chem Ind Co Ltd | ヒト抗ＨＢｓ抗体 |
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| AU2006211037B2 (en) * | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| WO2007146957A2 (en) | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
| WO2010124188A1 (en) | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| EP2998405B1 (en) * | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| EP2513146B1 (en) | 2009-12-18 | 2017-05-03 | Kancera AB | Antibodies against ror1 capable of inducing cell death of cll |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US9758586B2 (en) | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| CA2881981A1 (en) * | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CN105283201B (zh) * | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| JP2017522893A (ja) | 2014-07-31 | 2017-08-17 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｒｏｒ１特異的多重鎖キメラ抗原受容体 |
| RU2753512C2 (ru) * | 2014-09-08 | 2021-08-17 | Нэшнл Кэнсер Сентер | Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования |
| EP3204416A1 (en) | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP6865688B2 (ja) * | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| EP3253754B1 (en) | 2015-02-02 | 2021-03-31 | Kancera AB | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
| CA2981883C (en) * | 2015-04-14 | 2019-10-22 | Academia Sinica | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| EP3842072A1 (en) | 2015-05-18 | 2021-06-30 | Eureka Therapeutics, Inc. | Anti-ror1 antibodies |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| SG11201806120WA (en) | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
| KR20180100238A (ko) | 2016-01-22 | 2018-09-07 | 얀센 바이오테크 인코포레이티드 | 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| CN109563092B (zh) | 2016-07-11 | 2021-09-14 | 坎塞拉有限公司 | 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 |
| WO2018119314A1 (en) | 2016-12-22 | 2018-06-28 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| MX2019013998A (es) | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| WO2019005636A2 (en) | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| WO2019016381A1 (en) | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| AU2018360031B2 (en) | 2017-11-03 | 2025-08-21 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-ROR1 immunotherapy |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
| US11723926B2 (en) * | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
-
2017
- 2017-07-05 GB GBGB1710836.6A patent/GB201710836D0/en not_active Ceased
-
2018
- 2018-07-05 MX MX2019015352A patent/MX2019015352A/es unknown
- 2018-07-05 US US16/628,450 patent/US11723925B2/en active Active
- 2018-07-05 CN CN201880045348.9A patent/CN110997709B/zh active Active
- 2018-07-05 EP EP18742576.4A patent/EP3649150B1/en active Active
- 2018-07-05 CA CA3068197A patent/CA3068197A1/en active Pending
- 2018-07-05 JP JP2019572402A patent/JP7179030B2/ja active Active
- 2018-07-05 WO PCT/GB2018/051915 patent/WO2019008378A1/en not_active Ceased
- 2018-07-05 AU AU2018295478A patent/AU2018295478A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529838A5 (https=) | ||
| JP2020529839A5 (https=) | ||
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| JP2020530272A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| CN110088133A (zh) | 抗独特型抗体及相关方法 | |
| JP2021531764A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| WO2014165818A2 (en) | Compositions and methods for preventing and treating prostate cancer | |
| JP2018503380A5 (https=) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN113993903B (zh) | 一种抗pd-1和pd-l1的四价双特异性抗体 | |
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JPWO2021032157A5 (https=) | ||
| EP3600411A1 (en) | Antibodies for the treatment of erbb-2/erbb-3 positive tumors | |
| IL304295B1 (en) | A bispecific antibody with a heterodimeric form with a natural antibody structure ANTI-PD-L1/ANTI-4-1BB and its preparation | |
| US20230331852A1 (en) | Anti-clec-1a antibodies and antigen-binding fragment thereof | |
| Kelton et al. | Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule | |
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии | |
| CN112567244A (zh) | 靶向gasp-1颗粒的结合蛋白和嵌合抗原受体t细胞及其用途 | |
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| US20240025995A1 (en) | Dual targeted immune regulating compositions | |
| US12448454B2 (en) | Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof | |
| EP4314054A1 (en) | Anti-egfr single domain antibodies and therapeutic constructs |